America’s Essential Hospitals and 340B Health yesterday denounced GlaxoSmithKline’s (GSK) new restrictions on 340B pricing when hospitals use contract pharmacies. Pharmaceutical Research and Manufacturers of America (PhRMA) said this morning it will keep pushing for “much needed changes” to the 340B program.
“It’s clear the pharmaceutical industry has little regard for making affordable drugs accessible to low-income patients, and GlaxoSmithKline is just the latest sad example of that,” said Beth Feldpush, America’s Essential Hospitals’ senior vice president of policy and advocacy. “This restriction will do nothing more than pad GSK’s bottom line at the expense—and maybe the lives—of our most underrepresented and underserved people.”
America’s Essential Hospitals and 340B Health yesterday denounced GlaxoSmithKline’s (GSK) new restrictions on 340B pricing when hospitals use contract pharmacies. Pharmaceutical Research and Manufacturers of America (PhRMA) said this morning it will keep pushing for “much needed changes” to the 340B program.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.